scholarly journals Mesenchymal stem cell expression of stromal cell-derived factor-1β augments bone formation in a model of local regenerative therapy

2014 ◽  
Vol 33 (2) ◽  
pp. 174-184 ◽  
Author(s):  
Samuel Herberg ◽  
Galina Kondrikova ◽  
Khaled A. Hussein ◽  
Maribeth H. Johnson ◽  
Mohammed E. Elsalanty ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Bone Formation ◽  
Stromal Cell ◽  
Regenerative Therapy ◽  
Stromal Cell Derived Factor ◽  
Cell Expression

scholarly journals Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome

Blood ◽  
2012 ◽  
Vol 120 (15) ◽  
pp. 3142-3151 ◽  
Author(s):  
Junji Xu ◽  
Dandan Wang ◽  
Dayong Liu ◽  
Zhipeng Fan ◽  
Huayong Zhang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stromal Cell ◽  
Sjogren Syndrome ◽  
Stromal Cell Derived Factor ◽  
Stem Cell Treatment ◽  
Mesenchymal Stem Cell Treatment

Abstract Sjögren syndrome (SS) is a systemic autoimmune disease characterized by dry mouth and eyes, and the cellular and molecular mechanisms for its pathogenesis are complex. Here we reveal, for the first time, that bone marrow mesenchymal stem cells in SS-like NOD/Ltj mice and human patients were defective in immunoregulatory functions. Importantly, treatment with mesenchymal stem cells (MSCs) suppressed autoimmunity and restored salivary gland secretory function in both mouse models and SS patients. MSC treatment directed T cells toward Treg and Th2, while suppressing Th17 and Tfh responses, and alleviated disease symptoms. Infused MSCs migrated toward the inflammatory regions in a stromal cell–derived factor-1–dependent manner, as neutralization of stromal cell–derived factor-1 ligand CXCR4 abolished the effectiveness of bone marrow mesenchymal stem cell treatment. Collectively, our study suggests that immunologic regulatory functions of MSCs play an important role in SS pathogenesis, and allogeneic MSC treatment may provide a novel, effective, and safe therapy for patients with SS. This study was registered at www.clinicaltrials.gov as NCT00953485.

scholarly journals Intra-Articular Injection of Stromal Cell-Derived Factor 1α Promotes Meniscal Healing via Macrophage and Mesenchymal Stem Cell Accumulation in a Rat Meniscal Defect Model

2020 ◽  
Vol 21 (15) ◽  
pp. 5454
Author(s):  
Yohei Nishida ◽  
Yusuke Hashimoto ◽  
Kumi Orita ◽  
Kazuya Nishino ◽  
Takuya Kinoshita ◽  
...  
Keyword(s):  
Stem Cell ◽  
Treatment Group ◽  
Mesenchymal Stem Cell ◽  
Stromal Cell ◽  
Healing Process ◽  
Defect Model ◽  
Cell Accumulation ◽  
Meniscal Healing ◽  
Meniscus Healing ◽  
Stromal Cell Derived Factor

The stromal-cell-derived factor-1α (SDF-1) is well-known for playing important roles in the regeneration of tissue by enhancing cell migration. However, the effect of SDF-1 in meniscal healing remains unknown. The purpose of this study is to investigate the effects of intra-articular injection of SDF-1 on meniscus healing in a rat meniscal defect model. The intra-articular SDF-1 injection was performed at meniscectomy and one week later. Macroscopic and histological assessments of the reparative meniscus were conducted at one, two and six weeks after meniscectomy in rats. In the macroscopic evaluation, the SDF-1 group showed an increase in the size of the reparative meniscus at six weeks after meniscectomy compared to the phosphate-buffered saline (PBS) injection (no-treatment) group. Histological findings showed that intra-articular injection of SDF-1 enhanced the migration of macrophages to the site of the regenerative meniscus at one and two weeks after meniscectomy. CD68- and CD163-positive cells in the SDF-1 group at one week after meniscectomy were significantly higher than in the no-treatment group. CD163-positive cells in the SDF-1 group at two weeks were significantly higher than in the no-treatment group. At one week after meniscectomy, there were cells expressing mesenchymal-stem-cell-related markers in the SDF-1 group. These results indicate the potential of regenerative healing of the meniscus by SDF-1 injection via macrophage and mesenchymal stem cell accumulation. In the present study, intra-articular administration of SDF-1 contributed to meniscal healing via macrophage, CD90-positive cell and CD105-positive cell accumulation in a rat meniscal defect model. The SDF-1–CXCR4 pathway plays an important role in the meniscal healing process. For potential clinical translation, SDF-1 injection therapy seems to be a promising approach for the biological augmentation in meniscal injury areas to enhance healing capacity.

Sign in / Sign up

Export Citation Format

Share Document